Compare Illumina, Inc. (ILMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Illumina, Inc. is far larger — about 4× State Street SPDR S&P Biotech ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ILMN | XBI | |
|---|---|---|
Market Cap | $39.95B | $10.11B |
Volume | 3,169,503 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $293.69 | $169.55 |
52-Week Low | $91.00 | $104.99 |
Typical Hold Time | 83 Days | 38 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
